# Evommune, Inc. (EVMN) Press Releases

### Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
[Read more](https://ir.evommune.com/news-events/press-releases/detail/124/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-moderate-to-severe-chronic-spontaneous-urticaria)  
Mon, 29 Jun 26 08:30:00 -0400

### Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
[Read more](https://ir.evommune.com/news-events/press-releases/detail/123/evommune-reports-first-quarter-2026-financial-results-and-provides-business-highlights)  
Thu, 07 May 26 16:05:00 -0400

### Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
[Read more](https://ir.evommune.com/news-events/press-releases/detail/122/evommune-to-host-kol-webinar-on-april-13-2026-highlighting-the-potential-of-mrgprx2-inhibition-in-migraine)  
Mon, 06 Apr 26 09:00:00 -0400

### Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
[Read more](https://ir.evommune.com/news-events/press-releases/detail/121/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights)  
Thu, 05 Mar 26 16:01:00 -0500

### Evommune Announces $125 Million Private Placement
[Read more](https://ir.evommune.com/news-events/press-releases/detail/120/evommune-announces-125-million-private-placement)  
Thu, 12 Feb 26 20:30:00 -0500

### Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
[Read more](https://ir.evommune.com/news-events/press-releases/detail/119/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis)  
Tue, 10 Feb 26 07:30:00 -0500

### Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
[Read more](https://ir.evommune.com/news-events/press-releases/detail/118/evommune-reports-third-quarter-2025-financial-results-and-provides-business-update)  
Thu, 11 Dec 25 16:05:00 -0500

### Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
[Read more](https://ir.evommune.com/news-events/press-releases/detail/117/evommune-announces-closing-of-its-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares)  
Fri, 07 Nov 25 16:05:00 -0500

### Evommune Announces Pricing of its Initial Public Offering
[Read more](https://ir.evommune.com/news-events/press-releases/detail/116/evommune-announces-pricing-of-its-initial-public-offering)  
Wed, 05 Nov 25 19:45:00 -0500

### Evommune Announces Commencement of Initial Public Offering
[Read more](https://ir.evommune.com/news-events/press-releases/detail/115/evommune-announces-commencement-of-initial-public-offering)  
Thu, 30 Oct 25 06:30:00 -0400